igk has been researched along with Lymphoma--B-Cell* in 8 studies
8 other study(ies) available for igk and Lymphoma--B-Cell
Article | Year |
---|---|
Primary Low-Grade B-Cell Lymphoma of Skull With Translocation Between Immunoglobulin and Interferon Regulatory Factor 4 Genes.
Low-grade B-cell lymphoma with immunoglobulin ( Topics: Aged; Cell Cycle Proteins; Humans; Immunoglobulins; Interferon Regulatory Factors; Lymphoma, B-Cell; Male; Skull Neoplasms; Transcription Factors; Translocation, Genetic | 2020 |
[Clinicopathological features of follicular lymphoma in children].
Topics: Child; China; Female; Gene Rearrangement; Humans; Immunoglobulins; Immunohistochemistry; Immunophenotyping; In Situ Hybridization, Fluorescence; Interferon Regulatory Factors; Ki-67 Antigen; Lymphoma, B-Cell; Lymphoma, Follicular; Male; Neprilysin; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-bcl-6 | 2019 |
Primary Central Nervous System (CNS) Lymphoma B Cell Receptors Recognize CNS Proteins.
Primary lymphoma of the CNS (PCNSL) is a diffuse large B cell lymphoma confined to the CNS. To elucidate its peculiar organ tropism, we generated recombinant Abs (recAbs) identical to the BCR of 23 PCNSLs from immunocompetent patients. Although none of the recAbs showed self-reactivity upon testing with common autoantigens, they recognized 1547 proteins present on a large-scale protein microarray, indicating polyreactivity. Interestingly, proteins (GRINL1A, centaurin-α, BAIAP2) recognized by the recAbs are physiologically expressed by CNS neurons. Furthermore, 87% (20/23) of the recAbs, including all Abs derived from IGHV4-34 using PCNSL, recognized galectin-3, which was upregulated on microglia/macrophages, astrocytes, and cerebral endothelial cells upon CNS invasion by PCNSL. Thus, PCNSL Ig may recognize CNS proteins as self-Ags. Their interaction may contribute to BCR signaling with sustained NF-κB activation and, ultimately, may foster tumor cell proliferation and survival. These data may also explain, at least in part, the affinity of PCNSL cells for the CNS. Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Antibodies, Neoplasm; Astrocytes; Base Sequence; Blood Proteins; Carcinoma, Large Cell; Cell Proliferation; Central Nervous System Neoplasms; Endothelial Cells; Enzyme Activation; Female; Galectin 3; Galectins; Gene Expression Profiling; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Light Chains; Immunoglobulins; Lymphoma, B-Cell; Macrophages; Male; Microglia; Middle Aged; Nerve Tissue Proteins; NF-kappa B; Receptors, Antigen, B-Cell; RNA Polymerase II; Sequence Analysis, DNA | 2015 |
Clonal identity and differences in primary cutaneous B-cell lymphoma occurring at different sites or time points in the same patient.
Primary cutaneous B-cell lymphomas (PCBCL) are rare. Marginal zone lymphomas and follicle center lymphomas (FCL) represent a majority of these cases, and a significant number of cases present with multiple lesions. It is unclear whether multiple lesions in PCBCL represent dissemination of a single clone or multiple new primary lymphomas. In the current study, we analyzed paired samples from 20 PCBCL patients at more than 1 site (16) or at the same site at different time points (4) and 12 patients with benign lymphoid infiltrates to investigate for the presence or absence of a clone, and if present, whether the clones were identical. Both IGH@ and IGK@ rearrangements were tested using the BIOMED-2 protocol. We identified a clone (IGH@ and/or IGK@) in 19 of 20 (95%) PCBCL patients and 2 of 12 (17%) benign lymphoid infiltrate patients. The B-cell clones were proven to be identical in 11 of 20 (55%) PCBCL patients, including 7 of 16(44%) biopsies from patients with 2 different sites and 4 of 4 biopsies (100%) from patients at the same site but different time points. In 4 cases (3 FCL and 1 marginal zone lymphoma), different clones were detected at different sites, suggesting the possibility of a second simultaneous primary lymphoma. Our results indicate that the presence of identical clones is highly suggestive of lymphoma. To our knowledge, this is the first report to investigate the detection of identical clones in 2 distinct biopsies in PCBCL patients. Although the study is small and the results need to be confirmed in a larger study, these findings suggest that a subset of PCBCL at different sites may represent different primary tumors rather than occurrence of a single disease. Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antigens, CD20; Biomarkers, Tumor; Case-Control Studies; Clone Cells; Female; Gene Rearrangement; Humans; Immunoglobulin Heavy Chains; Immunoglobulins; Immunohistochemistry; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Male; Middle Aged; Neoplasms, Multiple Primary; Polymerase Chain Reaction; Skin Neoplasms | 2013 |
Sequencing of t(2;7) translocations reveals a consistent breakpoint linking CDK6 to the IGK locus in indolent B-cell neoplasia.
The translocation t(2;7)(p11;q21) has repeatedly been documented in association with indolent B-cell lymphoproliferative disorders (BLPDs). However, the chromosomal breakpoints associated with this recurrent translocation have rarely been characterized. Using an approach based on long-range PCR, we mapped the t(2;7) breakpoints in five patients presenting with indolent B-cell neoplasia. The sequencing of these rearrangements revealed several striking parallels across the t(2;7) breakpoints. The junction sites on 2p11 consistently mapped to the heptamer recombination signal sequence (RSS) of an immunoglobulin kappa variable gene (IGK) within the Vκ3 family, while the breakpoints on 7q21 each localized to within 4 bp of an RSS-like element located approximately 0.5 kb upstream of the transcription start site of the cyclin-dependent kinase 6 gene (CDK6). These findings confirm the significant genetic overlap arising in BLPD-associated t(2;7) translocations, and implicate the deregulated expression of CDK6 as a common molecular mechanism involved in the emergence of clonal B-cell proliferations presenting with this recurrent abnormality. In addition, the successful mapping of the t(2;7) translocations in each of five patients using a simple PCR-based protocol highlights the potential diagnostic utility of this approach during characterization of cases harboring analogous rearrangements. Topics: Aged; Chromosome Breakpoints; Chromosome Mapping; Chromosomes, Human, Pair 2; Chromosomes, Human, Pair 7; Cyclin-Dependent Kinase 6; DNA Mutational Analysis; Female; Genetic Loci; Humans; Immunoglobulins; In Situ Hybridization, Fluorescence; Lymphoma, B-Cell; Male; Middle Aged; Translocation, Genetic | 2013 |
Application of microfluidic technology to the BIOMED-2 protocol for detection of B-cell clonality.
The BIOMED-2 protocol is widely used for detecting clonality in lymphoproliferative disorders. The protocol requires multiple PCR reactions, which are analyzed by either capillary electrophoresis (GeneScan analysis) or heteroduplex PAGE analysis. We tested a microfluidic chip-based electrophoresis device (Agilent 2100 Bioanalyzer) for the analysis of B-cell clonality using PCR for the three framework subregions (FR) of the Ig heavy chain gene (IGH) and PCR for two rearrangements occurring in the Ig κ chain gene (IGK-VJ and IGK-DE). We analyzed 62 B-cell lymphomas (33 follicular and 29 nonfollicular) and 16 reactive lymph nodes. Chip-based electrophoresis was conclusive for monoclonality in 59/62 samples; for 20 samples, it was compared with GeneScan analysis. Concordant results were obtained in 45/55 IGH (FR1, FR2, and FR3) gene rearrangements, and in 34/37 IGK gene rearrangements. However, when the chip device was used to analyze selected IGK gene rearrangements (biallelic IGK rearrangements or IGK rearrangements in a polyclonal background), its performance was not completely accurate. We conclude, therefore, that this microfluidic chip-based electrophoresis device is reliable for testing cases with dominant PCR products but is less sensitive than GeneScan in detecting clonal peaks in a polyclonal background for IGH PCR, or with complex IGK rearrangement patterns. Topics: B-Lymphocytes; Electrophoresis, Microchip; Gene Rearrangement; Humans; Immunoglobulin Heavy Chains; Immunoglobulins; Lymph Nodes; Lymphoma, B-Cell; Sensitivity and Specificity | 2012 |
Novel FISH probes designed to detect IGK-MYC and IGL-MYC rearrangements in B-cell lineage malignancy identify a new breakpoint cluster region designated BVR2.
Detection of translocations involving MYC at 8q24.1 in B-cell lineage malignancies (BCL) is important for diagnostic and prognostic purposes. However, routine detection of MYC translocations is often hampered by the wide variation in breakpoint location within the MYC region, particularly when a gene other than IGH, such as IGK or IGL, is involved. To address this issue, we developed and validated four fluorescence in situ hybridization (FISH) probes: two break apart probes to detect IGK and IGL translocations, and two dual-color, dual-fusion FISH (D-FISH) probes to detect IGK-MYC and IGL-MYC. MYC rearrangements (four IGK-MYC, 12 IGL-MYC and four unknown partner gene-MYC) were correctly identified in 20 of 20 archival BCL specimens known to have MYC rearrangements not involving IGH. Seven specimens, all of which lacked MYC rearrangements using a commercial IGH/MYC D-FISH probe, were found to have 8q24 breakpoints within a cluster region >350-645 kb 3' from MYC, provisionally designated as Burkitt variant rearrangement region 2 (BVR2). FISH is a useful ancillary tool in identifying MYC rearrangements. In light of the discovery of the distally located BVR2 breakpoint cluster region, it is important to use MYC FISH probes that cover a breakpoint region at least 1.0 Mb 3' of MYC. Topics: B-Lymphocytes; Chromosomes, Artificial, Bacterial; DNA Probes; Gene Rearrangement, B-Lymphocyte; Genes, myc; Genetic Testing; Humans; Immunoglobulin Light Chains; Immunoglobulins; In Situ Hybridization, Fluorescence; Lymphoma, B-Cell; Translocation, Genetic | 2006 |
Immunoglobulin gene mutations and frequent use of VH1-69 and VH4-34 segments in hepatitis C virus-positive and hepatitis C virus-negative nodal marginal zone B-cell lymphoma.
Nodal marginal zone B-cell lymphoma (NMZL) is actually considered as a distinct entity that must be distinguished from extra-nodal and splenic marginal zone lymphomas. To define the cell origin and the role of antigen stimulation we determined the nucleotide sequence of the tumor-related immunoglobulin heavy chain variable genes in 10 cases of NMZL. The results were also evaluated on the basis of the presence of chronic hepatitis C virus (HCV) infection. All 10 cases harbored VH somatic mutations with a sequence homology compared to the closest germline gene, ranging from 83.33 to 98.28%. Interestingly, different VH segments were preferentially used in HCV-positive and HCV-negative patients: three of five HCV-negative NMZLs used a VH4-34 segment joined with different D and JH segments whereas three of five HCV-positive NMZLs used a VH1-69 gene joined with a D3-22 and a JH4 segment, with very strong similarities in the CDR3s among the three different cases. These data indicate: 1) NMZL is derived from B cells that have experienced the germinal center reaction; 2) the preferential usage of a VH1-69 segment in the majority of the HCV-positive NMZL cases with similar CDR3s suggests the presence of a common antigen, probably a HCV antigen epitope, involved in the B-cell selection; and 3) the use of a VH4-34 segment suggests a role of yet unknown B-cell superantigen(s) in the selection of tumor B-cell precursors in HCV-negative NMZL. Topics: Base Sequence; Gene Rearrangement; Hepacivirus; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Immunoglobulins; Lymphoma, B-Cell; Molecular Sequence Data; Mutation; Polymerase Chain Reaction | 2001 |